2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide
2022.1.0 - CI Build

2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide, published by Centers for Disease Control and Prevention (CDC). This guide is not an authorized publication; it is the continuous build for version 2022.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/opioid-cds-r4/ and changes regularly. See the Directory of published versions

Recommendation #10 - Urine Drug Testing

Note that this recommendation is represented in multiple variations where each variation corresponds to the CDS Hook by which it was meant to be triggered/evaluated. Use the tabs below to navigate to each variation.

CDC Guideline: 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain
Recommendation Topic: Selecting Opioids and Determining Opioid Dosages (Source)
Recommendation Description: When prescribing opioids for subacute or chronic pain, clinicians should consider the benefits and risks of toxicology testing to assess for prescribed medications as well as other prescribed and nonprescribed controlled substances. (Source)
Recommendation Category: B
Evidence Type: 4
Recommendation 10 Order Sign Flow DiagramOrder SignnoOpioid order forsubacute orchronic pain?noOpioid review useful?yesnoUrine toxicologyscreening inpast year?yesUDS AlertnoPossible unexpected resultsfound in urine toxicologyscreening?yesyesPossible UnexpectedResults AlertNo Alert**When no alert is warranted by the guidance, the user should not experience any interruption.
 EHR Triggering Event Calculation Logic Subroutine Calculation Logic User Interaction

  • When
    • Provider is prescribing an opioid analgesic with ambulatory misuse potential in the outpatient setting
      • Order for opioid analgesic with an expected supply duration of 28 days or longer or
      • Order in the past 90 days for opioid analgesic with therapy type of "continuous" or
      • Order for opioid analgesic for 28 of the past 90 days including today and
      • An active or pending order for opioid analgesic
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient problem list includes CDC malignant cancer condition, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Urine toxicology screening has not been performed in last 12 months
      • Opioid urine toxicology screening in past year, or
      • Nonopioid urine toxicology screening in past year
  • Then
    • Consider the benefits and risks of conducting a urine toxicology screen:
      • Document - Order toxicology screen
      • Document risks outweigh benefits
      • Snooze - N/A see comment, snooze 3 months
  • When
    • Provider is prescribing an opioid analgesic with ambulatory misuse potential in the outpatient setting
      • Order for opioid analgesic with an expected supply duration of 28 days or longer or
      • Order in the past 90 days for opioid analgesic with therapy type of "continuous" or
      • Order for opioid analgesic for 28 of the past 90 days including today and
      • An active or pending order for opioid analgesic
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient problem list includes CDC malignant cancer condition, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Urine toxicology screening has been performed in last 12 months
      • Opioid urine toxicology screening in past year, or
      • Nonopioid urine toxicology screening in past year
    • Possible unexpected results in urine toxicology
      • Positive result for a substance of potential interest in the past year or
      • Negative result for a prescribable substance in the past year and
      • An order for that substance exists in the 30 days prior to the test or
      • Positive result for a prescribable\n substance in the past year and
      • No order for that substance exists\n in the 30 days prior to the test
  • Then
    • Patient may have possible unexpected toxicology test results:
      • Document - Will repeat urine drug screening more frequently
      • Document - Will consult with patient regarding possible unexpected test results
      • Document - Will assess patient for substance use disorder
      • Snooze - Patient's test results were expected, snooze for 3 months
      • Snooze - N/A snooze for 3 months
The following table describes the flowchart decisions and sub-routines for the recommendation
Definition Answer to Proceed Details Data (Terminology) Requirement Profile Path
Order for opioid analgesic with ambulatory misuse potential Yes Order for opioid analgesics with ambulatory misuse potential Opioid analgesics with ambulatory misuse potential MedicationRequest MedicationRequest.medication, and MedicationRequest.category
Opioid order for subacute or chronic pain? Yes See For Subacute or Chronic Pain sub-routine
Opioid review useful? Yes See Opioid Review Useful sub-routine
Urine toxicology screening in past year? Yes See Urine Toxicology Screening in Past Year sub-routine
Possible unexpected results found in toxicology screening? Yes See Possible Unexpected Results in Toxicology Screening sub-routine

Effective Data Requirements

The following artifacts formalize the description of the logic and behavior defined by this recommendation.

Resource Type Description
2022 CDC Clinical Practice Guideline Recommendation #10 Order Sign PlanDefinition Event-Condition-Action rule that implements behavior for 2022 CDC Clinical Practice Guideline Recommendation #10 Order Sign
Recommendation #10 Order Sign - urine drug testing when prescribing opioids for subacute or chronic pain Library Defines the data requirements to support evaluation of recommendation #10 Order Sign
Opioid Terminology Management Knowledge-base Data (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Opioid Terminology Management Knowledge-base (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Common Opioid Decision Support LogicLibraryCQL Library that provides common logic for the recommendations
Common OpioidCDS Configuration LogicLibraryCQL Library that provides common configuration logic for the recommendations
Common OpioidCDS Routines LogicLibraryCQL Library that provides common routines logic for the recommendations
FHIRHelpers Conversion LogicLibraryCQL Library that defines functions to convert between FHIR data types and CQL system-defined types, as well as functions to support FHIRPath implementation
DescriptionCDS Hooks RequestExpected Response
Patient 18 or older. Patient is being prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RxNorm code 197696), once every 12 days for 30 days. This triggers the message that urine drug screening is recommended with the following three feedback options:
i. Perform the screening
ii. Indicate that the prescription is not for subacute or chronic pain management and snooze for 3 months
iii. Indicate that it is not applicable, log a comment and snooze for 3 months. 		Request JSON Response JSON
Patient 18 or older. Patient is being prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RxNorm code 197696) and a urine screening with the prescence of Phencyclidine is present. This triggers the message "Positive Cocaine or PCP in Urine Screening" with a note explaining this may be a false positive or indicate recreational or addictive use. Request JSON Response JSON
  • When
    • Provider is prescribing an opioid analgesic with ambulatory misuse potential in the outpatient setting
      • Order for opioid analgesic with an expected supply duration of 28 days or longer or
      • Order in the past 90 days for opioid analgesic with therapy type of "continuous" or
      • Order for opioid analgesic for 28 of the past 90 days including today and
      • An active or pending order for opioid analgesic
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient problem list includes CDC malignant cancer condition, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Urine toxicology screening has not been performed in last 12 months
      • Opioid urine toxicology screening in past year, or
      • Nonopioid urine toxicology screening in past year
  • Then
    • Consider the benefits and risks of conducting a urine toxicology screen:
      • Document - Order toxicology screen
      • Document risks outweigh benefits
      • Snooze - N/A see comment, snooze 3 months
  • When
    • Provider is prescribing an opioid analgesic with ambulatory misuse potential in the outpatient setting
      • Order for opioid analgesic with an expected supply duration of 28 days or longer or
      • Order in the past 90 days for opioid analgesic with therapy type of "continuous" or
      • Order for opioid analgesic for 28 of the past 90 days including today and
      • An active or pending order for opioid analgesic
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient problem list includes CDC malignant cancer condition, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Urine toxicology screening has been performed in last 12 months
      • Opioid urine toxicology screening in past year, or
      • Nonopioid urine toxicology screening in past year
    • Possible unexpected results in urine toxicology
      • Positive result for a substance of potential interest in the past year or
      • Negative result for a prescribable substance in the past year and
      • An order for that substance exists in the 30 days prior to the test or
      • Positive result for a prescribable\n substance in the past year and
      • No order for that substance exists\n in the 30 days prior to the test
  • Then
    • Patient may have possible unexpected toxicology test results:
      • Document - Will repeat urine drug screening more frequently
      • Document - Will consult with patient regarding possible unexpected test results
      • Document - Will assess patient for substance use disorder
      • Snooze - Patient's test results were expected, snooze for 3 months
      • Snooze - N/A snooze for 3 months

The following table describes the flowchart decisions and sub-routines for the recommendation
Definition Answer to Proceed Details Data (Terminology) Requirement Profile Path
Order for opioid analgesic with ambulatory misuse potential Yes Order for opioid analgesics with ambulatory misuse potential Opioid analgesics with ambulatory misuse potential MedicationRequest MedicationRequest.medication, and MedicationRequest.category
Opioid order for subacute or chronic pain? Yes See For Subacute or Chronic Pain sub-routine
Opioid review useful? Yes See Opioid Review Useful sub-routine
Urine toxicology screening in past year? Yes See Urine Toxicology Screening in Past Year sub-routine
Possible unexpected results found in toxicology screening? Yes See Possible Unexpected Results in Toxicology Screening sub-routine

Effective Data Requirements

The following artifacts formalize the description of the logic and behavior defined by this recommendation.

Resource Type Description
2022 CDC Clinical Practice Guideline Recommendation #10 Order Sign PlanDefinition Event-Condition-Action rule that implements behavior for 2022 CDC Clinical Practice Guideline Recommendation #10 Order Sign
Recommendation #10 Order Sign - urine drug testing when prescribing opioids for subacute or chronic pain Library Defines the data requirements to support evaluation of recommendation #10 Order Sign
Opioid Terminology Management Knowledge-base Data (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Opioid Terminology Management Knowledge-base (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Common Opioid Decision Support LogicLibraryCQL Library that provides common logic for the recommendations
Common OpioidCDS Configuration LogicLibraryCQL Library that provides common configuration logic for the recommendations
Common OpioidCDS Routines LogicLibraryCQL Library that provides common routines logic for the recommendations
FHIRHelpers Conversion LogicLibraryCQL Library that defines functions to convert between FHIR data types and CQL system-defined types, as well as functions to support FHIRPath implementation

DescriptionCDS Hooks RequestExpected Response
Patient 18 or older. Patient is being prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RxNorm code 197696), once every 12 days for 30 days. This triggers the message that urine drug screening is recommended with the following three feedback options:
i. Perform the screening
ii. Indicate that the prescription is not for subacute or chronic pain management and snooze for 3 months
iii. Indicate that it is not applicable, log a comment and snooze for 3 months. 		Request JSON Response JSON
Patient 18 or older. Patient is being prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RxNorm code 197696) and a urine screening with the prescence of Phencyclidine is present. This triggers the message "Positive Cocaine or PCP in Urine Screening" with a note explaining this may be a false positive or indicate recreational or addictive use. Request JSON Response JSON
CDC Guideline: 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain
Recommendation Topic: Selecting Opioids and Determining Opioid Dosages (Source)
Recommendation Description: When prescribing opioids for subacute or chronic pain, clinicians should consider the benefits and risks of toxicology testing to assess for prescribed medications as well as other prescribed and nonprescribed controlled substances. (Source)
Recommendation Category: B
Evidence Type: 4
Recommendation 10 Patient View Flow DiagramPatient ViewnoActive opioid order for subacuteor chronic pain?noOpioid review useful?yesnoUrine toxicologyscreening inpast year?yesUDS AlertnoPossible unexpected resultsfound in urine toxicologyscreening?yesyesPossible UnexpectedResults AlertNo Alert**When no alert is warranted by the guidance, the user should not experience any interruption.
 EHR Triggering Event Calculation Logic Subroutine Calculation Logic User Interaction

  • When
    • There exists an opioid analgesic with ambulatory misuse potential in the outpatient setting
      • Order for opioid analgesic with an expected supply duration of 28 days or longer or
      • Order in the past 90 days for opioid analgesic with therapy type of "continuous" or
      • Order for opioid analgesic for 28 of the past 90 days including today and
      • An active or pending order for opioid analgesic
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient problem list includes CDC malignant cancer condition, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Urine toxicology screening has not been performed in last 12 months
      • Opioid urine toxicology screening in past year, or
      • Nonopioid urine toxicology screening in past year
  • Then
    • Consider the benefits and risks of conducting a urine toxicology screen:
      • Document - Order toxicology screen
      • Document risks outweigh benefits
      • Snooze - N/A see comment, snooze 3 months
  • When
    • There exists an opioid analgesic with ambulatory misuse potential in the outpatient setting
      • Order for opioid analgesic with an expected supply duration of 28 days or longer or
      • Order in the past 90 days for opioid analgesic with therapy type of "continuous" or
      • Order for opioid analgesic for 28 of the past 90 days including today and
      • An active or pending order for opioid analgesic
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient problem list includes CDC malignant cancer condition, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Urine toxicology screening has been performed in last 12 months
      • Opioid urine toxicology screening in past year, or
      • Nonopioid urine toxicology screening in past year
    • Possible unexpected results in urine toxicology
      • Positive result for a substance of potential interest in the past year or
      • Negative result for a prescribable substance in the past year and
      • An order for that substance exists in the 30 days prior to the test or
      • Positive result for a prescribable\n substance in the past year and
      • No order for that substance exists\n in the 30 days prior to the test
  • Then
    • Patient may have unexpected toxicology test results:
      • Document - Will repeat urine drug screening more frequently
      • Document - Will consult with patient regarding possible unexpected test results
      • Document - Will assess patient for substance use disorder
      • Snooze - Patient's test results were expected, snooze for 3 months
      • Snooze - N/A snooze for 3 months
The following table describes the flowchart decisions and sub-routines for the recommendation
Definition Answer to Proceed Details Data (Terminology) Requirement Profile Path
There exists an active opioid analgesic with ambulatory misuse potential order in the outpatient setting Yes Order for opioid analgesics with ambulatory misuse potential Opioid analgesics with ambulatory misuse potential MedicationRequest MedicationRequest.medication, and MedicationRequest.category
Opioid order for subacute or chronic pain? Yes See For Subacute or Chronic Pain sub-routine
Opioid review useful? Yes See Opioid Review Useful sub-routine
Urine toxicology screening in past year? Yes See Urine Toxicology Screening in Past Year sub-routine
Possible unexpected results found in toxicology screening? Yes See Possible Unexpected Results in Toxicology Screening sub-routine

Effective Data Requirements

The following artifacts formalize the description of the logic and behavior defined by this recommendation.

Resource Type Description
2022 CDC Clinical Practice Guideline Recommendation #10 Patient View PlanDefinition Event-Condition-Action rule that implements behavior for 2022 CDC Clinical Practice Guideline Recommendation #10 Patient View
Recommendation #10 Patient View - urine drug testing when prescribing opioids for subacute or chronic pain Library Defines the data requirements to support evaluation of recommendation #10 Patient View
Opioid Terminology Management Knowledge-base Data (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Opioid Terminology Management Knowledge-base (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Common Opioid Decision Support LogicLibraryCQL Library that provides common logic for the recommendations
Common OpioidCDS Configuration LogicLibraryCQL Library that provides common configuration logic for the recommendations
Common OpioidCDS Routines LogicLibraryCQL Library that provides common routines logic for the recommendations
FHIRHelpers Conversion LogicLibraryCQL Library that defines functions to convert between FHIR data types and CQL system-defined types, as well as functions to support FHIRPath implementation
DescriptionCDS Hooks RequestExpected Response
Patient 18 or older. Patient is being prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RxNorm code 197696), once every 12 days for 30 days.
This triggers the message that urine drug screening is recommended with the following three feedback options:
i. Perform the screening
ii. Indicate that the prescription is not for subacute or chronic pain management and snooze for 3 months
iii. Indicate that it is not applicable, log a comment and snooze for 3 months. 		Request JSON Response JSON
Patient 18 or older. Patient is being prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RxNorm code 197696), once every 12 days for 30 days. Patient has condition indicating end of life (Carcinoma of endocrine pancreas). The patient will be excluded and no message will be triggered - an empty set of cards will be returned. Request JSON Response JSON
  • When
    • There exists an opioid analgesic with ambulatory misuse potential in the outpatient setting
      • Order for opioid analgesic with an expected supply duration of 28 days or longer or
      • Order in the past 90 days for opioid analgesic with therapy type of "continuous" or
      • Order for opioid analgesic for 28 of the past 90 days including today and
      • An active or pending order for opioid analgesic
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient problem list includes CDC malignant cancer condition, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Urine toxicology screening has not been performed in last 12 months
      • Opioid urine toxicology screening in past year, or
      • Nonopioid urine toxicology screening in past year
  • Then
    • Consider the benefits and risks of conducting a urine toxicology screen:
      • Document - Order toxicology screen
      • Document risks outweigh benefits
      • Snooze - N/A see comment, snooze 3 months
  • When
    • There exists an opioid analgesic with ambulatory misuse potential in the outpatient setting
      • Order for opioid analgesic with an expected supply duration of 28 days or longer or
      • Order in the past 90 days for opioid analgesic with therapy type of "continuous" or
      • Order for opioid analgesic for 28 of the past 90 days including today and
      • An active or pending order for opioid analgesic
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient problem list includes CDC malignant cancer condition, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Urine toxicology screening has been performed in last 12 months
      • Opioid urine toxicology screening in past year, or
      • Nonopioid urine toxicology screening in past year
    • Possible unexpected results in urine toxicology
      • Positive result for a substance of potential interest in the past year or
      • Negative result for a prescribable substance in the past year and
      • An order for that substance exists in the 30 days prior to the test or
      • Positive result for a prescribable\n substance in the past year and
      • No order for that substance exists\n in the 30 days prior to the test
  • Then
    • Patient may have unexpected toxicology test results:
      • Document - Will repeat urine drug screening more frequently
      • Document - Will consult with patient regarding possible unexpected test results
      • Document - Will assess patient for substance use disorder
      • Snooze - Patient's test results were expected, snooze for 3 months
      • Snooze - N/A snooze for 3 months

The following table describes the flowchart decisions and sub-routines for the recommendation
Definition Answer to Proceed Details Data (Terminology) Requirement Profile Path
There exists an active opioid analgesic with ambulatory misuse potential order in the outpatient setting Yes Order for opioid analgesics with ambulatory misuse potential Opioid analgesics with ambulatory misuse potential MedicationRequest MedicationRequest.medication, and MedicationRequest.category
Opioid order for subacute or chronic pain? Yes See For Subacute or Chronic Pain sub-routine
Opioid review useful? Yes See Opioid Review Useful sub-routine
Urine toxicology screening in past year? Yes See Urine Toxicology Screening in Past Year sub-routine
Possible unexpected results found in toxicology screening? Yes See Possible Unexpected Results in Toxicology Screening sub-routine

Effective Data Requirements

The following artifacts formalize the description of the logic and behavior defined by this recommendation.

Resource Type Description
2022 CDC Clinical Practice Guideline Recommendation #10 Patient View PlanDefinition Event-Condition-Action rule that implements behavior for 2022 CDC Clinical Practice Guideline Recommendation #10 Patient View
Recommendation #10 Patient View - urine drug testing when prescribing opioids for subacute or chronic pain Library Defines the data requirements to support evaluation of recommendation #10 Patient View
Opioid Terminology Management Knowledge-base Data (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Opioid Terminology Management Knowledge-base (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Common Opioid Decision Support LogicLibraryCQL Library that provides common logic for the recommendations
Common OpioidCDS Configuration LogicLibraryCQL Library that provides common configuration logic for the recommendations
Common OpioidCDS Routines LogicLibraryCQL Library that provides common routines logic for the recommendations
FHIRHelpers Conversion LogicLibraryCQL Library that defines functions to convert between FHIR data types and CQL system-defined types, as well as functions to support FHIRPath implementation

DescriptionCDS Hooks RequestExpected Response
Patient 18 or older. Patient is being prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RxNorm code 197696), once every 12 days for 30 days.
This triggers the message that urine drug screening is recommended with the following three feedback options:
i. Perform the screening
ii. Indicate that the prescription is not for subacute or chronic pain management and snooze for 3 months
iii. Indicate that it is not applicable, log a comment and snooze for 3 months. 		Request JSON Response JSON
Patient 18 or older. Patient is being prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RxNorm code 197696), once every 12 days for 30 days. Patient has condition indicating end of life (Carcinoma of endocrine pancreas). The patient will be excluded and no message will be triggered - an empty set of cards will be returned. Request JSON Response JSON